Entrada Therapeutics (TRDA) EBIT Margin (2023 - 2026)
Entrada Therapeutics (TRDA) posted quarterly EBIT Margin of 4834.63% for Q1 2026, down 472864.0% year-over-year from N/an in Q1 2025, and down 48.79% quarter-over-quarter from 3249.27% in Q4 2025.
Powered by 
Analysis
Entrada Therapeutics (TRDA) EBIT Margin (2023 - 2026) Analysis & Trends
Entrada Therapeutics' EBIT Margin history runs 4 years deep, the most recent figure standing at 4834.63% for Q1 2026.
- In Q1 2026, EBIT Margin fell 472864.0% year-over-year to 4834.63%; the TTM figure through Mar 2026 stood at 3109.29% (down 311167.0% YoY), while the FY2025 annual figure was 621.13%, down 64344.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 4834.63%, down from 3249.27% in the prior quarter.
- The five-year high for EBIT Margin was 56.42% in Q2 2024, with the low at 4834.63% in Q1 2026.
- The 4-year median for EBIT Margin is 89.7% (2023), against an average of 1046.97%.
- The sharpest annual moves came in 2024 and 2026: EBIT Margin soared 14612 bps in 2024, then tumbled 472864 bps in 2026.
- Entrada Therapeutics' EBIT Margin stood at 11.72% in 2023, then slumped by 234 bps to 15.69% in 2024, then slumped by 20612 bps to 3249.27% in 2025, then sank by 49 bps to 4834.63% in 2026.
- Business Quant data shows TRDA's EBIT Margin at 4834.63% in Q1 2026, 3249.27% in Q4 2025, and 2915.18% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Entrada Therapeutics | 297.03 Mn | 297.03 Mn | - | -5,007.02% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -5,007.02% |
| Mar 31, 2026 | -4,834.63% |
| Dec 31, 2025 | -3,249.27% |
| Sep 30, 2025 | -2,915.18% |
| Jun 30, 2025 | -2,402.51% |
| Mar 31, 2025 | -105.99% |
| Dec 31, 2024 | -15.69% |
| Sep 30, 2024 | -110.67% |
| Jun 30, 2024 | 56.42% |
| Mar 31, 2024 | 35.71% |
| Dec 31, 2023 | 11.72% |
| Sep 30, 2023 | 32.04% |
| Jun 30, 2023 | -89.70% |
| Mar 31, 2023 | -22.88% |